NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
10 trialsNCT01130623 2017-07-02
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01236586 2017-07-02
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02194452 2017-04-28
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
University of Iowa
Phase NA Withdrawn
NCT02521090 2016-02-15
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT02599090 2015-11-06
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00433472 2015-07-29
MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Withdrawn
NCT02055196 2014-06-02
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT00021307 2013-07-11
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Fox Chase Cancer Center
Phase 1/2 Withdrawn
NCT00003564 2012-02-22
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
M.D. Anderson Cancer Center
Phase 3 Withdrawn